Clinical Trial Update: A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC) [Phase 2, Phase 3]

View source ↗

Summary

Phase IIb/III study update for Prof-001 in recurrent vulvovaginal candidiasis is ongoing with phases 2 and 3 indicated; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvovaginal Candidiasis

Drugs mentioned

• ProF-001

Snippet

Sponsor: ProFem GmbH | Conditions: Recurrent Vulvovaginal Candidiasis | Phase 2, Phase 3 | Status: UNKNOWN